The purpose of this article is to review the recent clinically relevant literature on testicular cancer.
Introduction
Testicular cancer is the most common solid tumor in young men. Although most patients are highly curable, a subset of patients have a grim prognosis. Research in testicular cancer continues to work towards improving our understanding of the nature of the disease and its treatment. McGlynn et al. [1••] analyzed testicular germ cell tumor (TGCT) data from the Surveillance, Epidemiology, and End Results Program from 1973 to 1998 and noted changing trends over this period in both white and black patients. The overall incidence of TGCT rose from 3.35 per 100,000 to 4.84 per 100,000 men, and the incidence in white men remained higher than the rates in black men. Diverging rates of seminoma and nonseminoma, with an increasing proportion of seminomas seen in both black and white men, suggest a changing pattern in histologic appearance of the tumors. A dominant birthcohort effect was seen on age-period-cohort modeling of incidence data in white men and suggests that the increasing incidence is a result of changes in exposure to etiologic factors. Ekbom et al. [2•] identified a group of 93,172 Finnish men who immigrated to Sweden between 1969 and 1996 and monitored them for testicular cancer. Although the incidence of testicular cancer in Sweden is twice that in Finland, the cohort of immigrants had a reduced risk of both seminoma and nonseminoma consistent with their homeland population. Additionally, the risk of testicular cancer in the cohort was not associated with age at immigration or duration of stay. The results support a birth-cohort effect in the incidence of TGCT, and the authors hypothesize that the lifetime risk is determined early in life, possibly before birth.
Epidemiology and risk factors
Recent literature suggests an association between HIV and the development of GCT. Powles et al. [3••] published a study on the clinical history of 35 patients identified with HIV-related GCT. Seminomas were seen in 26 (74%) patients, and nonseminomatous germ cell tumors (NSGCTs) were found in the remaining 9 (26%). A significantly higher incidence of GCT was seen in HIVpositive patients than in a control HIV-negative population, but no difference in incidence in the HIV-positive population during the pre-and post-highly active antiretroviral therapy (HAART) eras was noted. The overall relative risk of HIV-related GCT was reported at 4.36. Seminoma occurred at a significantly higher frequency in HIV-positive patients than in the control population (relative risk 5.45), but no difference in incidence was seen with NSGCT. The authors speculate that this increased rate of seminomas may be secondary to immunosuppression related to HAART, and they suggest that these patients be treated similarly to HIV-negative patients. The prognostic value of teratoma at orchiectomy on RPLND findings was evaluated in a retrospective review of 644 patients who underwent RPLND after receiving chemotherapy. Teratoma in the retroperitoneum was found in 85.6% of patients who had teratoma in their orchiectomy specimens, and retroperitoneal teratoma was also seen in 48% of patients who did not have teratoma in their primary tumor. A larger retroperitoneal tumor volume was associated with a higher likelihood of teratoma being present at RPLND. The authors conclude that the absence of teratomatous elements in the orchiectomy specimen is not predictive of RPLND findings, and its absence at orchiectomy should not play a role in the decision whether or not to perform RPLND after chemotherapy [12•].
Markers and prognosis

Surveillance
Two studies investigated the utility of surveillance in stage I TGCT. 
Long-term toxicities
Recently, a group of investigators published a study assessing risk factors for bleomycin pulmonary toxicity. They examined a prospectively collected GCT research database and identified 835 patients who had been treated with a bleomycin-containing regimen for GCT between January 1982 and December 1999 and had a median follow-up time of 7.4 years. Within this cohort, 57 (6.8%) patients were found who had bleomycin pulmonary toxicity, and 8 of these cases (14%) proved to be fatal. The median time from first bleomycin administration to diagnosis of lung toxicity was 4.2 months (range 1.2-8.2). Four factors were identified with an increased risk of pulmonary toxicity that reached statistical significance on multivariate and univariate analyses. These included a glomerular filtration rate below 80 mL/min, stage IV disease, age greater than 40 years, or cumulative dose of bleomycin greater than 300,000 IU. so within 1 year. For comparison, the authors stated that up to one third of couples in the general population have fertility problems. Before receiving adjuvant therapy, 121 patients were offered cryopreservation, and 99 participated, with 78 providing adequate specimens. After treatment, 13 of these patients attempted artificial insemination, and 7 were successful. Thirty-three patients experienced ejaculatory problems after treatment, and 7 recovered function. The patients also were asked to evaluate information they received before therapy in regard to fertility and sexual function. Whereas 63% were satisfied, it is remarkable that 27% considered the materials provided to be less than adequate, and another 10% reported that they received no information. Given the rates of patients who continue to try to conceive after therapy, and the level of patient dissatisfaction regarding treatment-related conception materials, care should be given in informing patients about the risks of infertility and cryopreservation before any adjuvant therapy is given.
Conclusion
Testicular cancer remains an active area of cancer research. Although previous advances in its treatment are historic events in the war against cancer, much work has yet to be done. Investigators must continue to strive to identify patient and tumor characteristics that are predictive of outcome and response to therapy so as to minimize the numbers of patients that are exposed to the potential risks of adjuvant therapy.
